Abstract
It has been recently demonstrated that two serotypes of type D simian retroviruses, namely SRV-1 and SRV-2, exhibit extensive immunological cross-reactivity but do not exhibit cross-reactivity at the level of neutralizing antibodies. We have also shown recently that an area which includes residues 147-162 of the envelope protein of SRV-1 constitutes an epitope to which neutralizing antibodies against SRV-1 but not against SRV-2 are directed. However, in spite of the capacity of various immunogenic preparations to induce antibodies which react with SRV-1 these antibodies were incapable of neutralizing in vitro viral infectivity. Work reported herein demonstrates that various immunogens consisting of a larger peptide, namely 142-167 of the envelope protein of SRV-1, induce antibodies capable of binding with the envelope protein of SRV-1 and with the whole virus. Moreover, these antibodies exhibit the capacity to neutralize in vitro the infectivity of SRV-1 but not of SRV-2.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 907-913 |
| Number of pages | 7 |
| Journal | Molecular Immunology |
| Volume | 28 |
| Issue number | 8 |
| DOIs | |
| State | Published - 1991 |
Fingerprint
ASJC Scopus subject areas
- Molecular Biology
- Immunology
Cite this
The induction of neutralizing antibodies by synthetic peptides of the envelope protein of type D simian retrovirus-1 (SRV-1). / Torres, Jose V; Werner, Linda L.; Malley, Arthur; Benjamini, Eli.
In: Molecular Immunology, Vol. 28, No. 8, 1991, p. 907-913.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The induction of neutralizing antibodies by synthetic peptides of the envelope protein of type D simian retrovirus-1 (SRV-1)
AU - Torres, Jose V
AU - Werner, Linda L.
AU - Malley, Arthur
AU - Benjamini, Eli
PY - 1991
Y1 - 1991
N2 - It has been recently demonstrated that two serotypes of type D simian retroviruses, namely SRV-1 and SRV-2, exhibit extensive immunological cross-reactivity but do not exhibit cross-reactivity at the level of neutralizing antibodies. We have also shown recently that an area which includes residues 147-162 of the envelope protein of SRV-1 constitutes an epitope to which neutralizing antibodies against SRV-1 but not against SRV-2 are directed. However, in spite of the capacity of various immunogenic preparations to induce antibodies which react with SRV-1 these antibodies were incapable of neutralizing in vitro viral infectivity. Work reported herein demonstrates that various immunogens consisting of a larger peptide, namely 142-167 of the envelope protein of SRV-1, induce antibodies capable of binding with the envelope protein of SRV-1 and with the whole virus. Moreover, these antibodies exhibit the capacity to neutralize in vitro the infectivity of SRV-1 but not of SRV-2.
AB - It has been recently demonstrated that two serotypes of type D simian retroviruses, namely SRV-1 and SRV-2, exhibit extensive immunological cross-reactivity but do not exhibit cross-reactivity at the level of neutralizing antibodies. We have also shown recently that an area which includes residues 147-162 of the envelope protein of SRV-1 constitutes an epitope to which neutralizing antibodies against SRV-1 but not against SRV-2 are directed. However, in spite of the capacity of various immunogenic preparations to induce antibodies which react with SRV-1 these antibodies were incapable of neutralizing in vitro viral infectivity. Work reported herein demonstrates that various immunogens consisting of a larger peptide, namely 142-167 of the envelope protein of SRV-1, induce antibodies capable of binding with the envelope protein of SRV-1 and with the whole virus. Moreover, these antibodies exhibit the capacity to neutralize in vitro the infectivity of SRV-1 but not of SRV-2.
UR - http://www.scopus.com/inward/record.url?scp=0025863792&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025863792&partnerID=8YFLogxK
U2 - 10.1016/0161-5890(91)90055-O
DO - 10.1016/0161-5890(91)90055-O
M3 - Article
C2 - 1652065
AN - SCOPUS:0025863792
VL - 28
SP - 907
EP - 913
JO - Molecular Immunology
JF - Molecular Immunology
SN - 0161-5890
IS - 8
ER -